Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3
July 30, 2025
We’re excited to announce that the PanTracer product portfolio is expanding. PanTracer LBx, our new liquid biopsy solution, is now available to order.
PanTracer LBx is a minimally invasive test, delivering comprehensive, clinically actionable insights from a simple blood draw. The PanTracer LBx assay is guideline driven, testing for over 500 genes, and results are reported quickly, within 7 days, to enable real-time decision making.
The PanTracer portfolio reflects our commitment to evolving with the needs of oncology care—offering tests that are practical, powerful, and designed to support real-world clinical decisions. We are excited to share this latest evolution with you. For more info, please contact your local NeoGenomics Sales Representative or visit our website
Learn more about the PanTracer LBx and order today!
Effective today, July 30th, 2025, our existing liquid biopsy tests have been retired in favor of our new, upgraded liquid biopsy test, NEO | PanTracer™ LBx.
Retired tests:
- InVisionFirst®- Lung
- NeoLAB® Solid Tumor
Replacement test:
NEO | PanTracer LBx is a comprehensive genomic profiling liquid biopsy test assessing over 500 genes by ctDNA sequencing. PanTracer LBx contains broader, more updated gene content, which better aligns with clinical practice guidelines and is available for advanced stage solid tumor patients. For additional information on PanTracer LBx, please visit our website.
Claudin18.2 is an actionable biomarker for patients with advanced or metastatic Gastric/GEJ Adenocarcinoma
Approximately 70% of advanced G/GEJ cancers express CLDN18.2 at any amount.1 Of advanced G/GEJ cancers that express CLDN18.2, 38% express moderate to high levels that indicate eligibility for targeted therapy.2,3
Develop personalized treatment plans for gastric/GEJ cancer patients by identifying those who may benefit from targeted therapies. To learn about CLDN18.2 testing, please visit our website.
References:
1. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med (Epub) 10-26-2021.
2. Shitara K, Lordick F, Bang YJ, et al. Lancet 2023 Apr 14:S0140-6736(23)00620-7.
3. Xu RH, Shitara K, Ajani JA, et al. #405736. Presented at: March American Society of Clinical Oncology Plenary Series; March 22, 2023.